Skip to main content
Signal8

Lunai Bioworks Inc. (LNAI) Form 10-Q — May 15, 2026

$LNAIForm 10-QFiled May 15, 2026, 4:46 PM ET0001731122-26-000749Original filing

Lunai Bioworks reported a net loss of $1.55 million for the nine months ended March 31, 2026, with minimal revenue of $20,942 from a single research services contract. The company holds only $3.16 million in cash against a working capital deficit of $15.55 million and an accumulated deficit of $512 million, prompting explicit going-concern language in the financial statements. The filing discloses severe capital structure distress, including a 1-for-10 reverse stock split effective in September 2025 and a subsequent board approval for a further reverse split ranging from 1:3 to 1:30 to maintain Nasdaq listing compliance.

Key figures

Revenue
20942
Total Debt
19413968
Cash Position
3155272
Shares Outstanding
35772800
Atm Proceeds
4499551
Gain On Bankruptcy
12019227
Reverse Split Ratio
1:10 (effective Sept 2025)
Proposed Reverse Split Range
1:3 to 1:30

Price after filing

1 day: 0.0%7 days: +4.9%30 days: +803.8%

Close on the filing date to close N calendar days later (from $0.28). Historical, not a forecast.

AI analysis

Red flags8 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.